An exploratory study of the use of advance directives by US oncologists.

Umesh Sharma(Guru Nanak Eye Centre), Ronald S. Go(Mayo Clinic), Jonean E. Schroeder(Gundersen Lutheran Hospital), K. A. Frisby(Gundersen Lutheran Hospital), Mohammed Al-Hamadani(Gundersen Lutheran Hospital), L. A. Meyer(Gundersen Lutheran Hospital), Michelle A. Mathiason(Twin Cities Orthopedics), Christine Meyer(Gundersen Lutheran Hospital), Debbie L. Sieber(Gundersen Lutheran Hospital)

PubMed

August 1, 2013

Cited by 7

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

|The Lancet|2008|862

Measuring teacher efficacy to implement inclusive practices

|Journal of Research in Special Educational Needs|2011|752

Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin

|Journal of Clinical Oncology|1999|697

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

|Journal of Clinical Oncology|2012|682